Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.36 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14335532 | 0.95 | ALDH1A1 (0.36) | LPAR3LPAR2ALDH1A1CYP3A4TSHR | |
| SCHEMBL1949595 | 0.85 | ALOX12 (0.38) | ALDH1A1CYP3A4TSHRALOX12SMN1; SMN2 | |
| SCHEMBL13748507 | 0.85 | ALOX12 (0.38) | ALDH1A1CYP3A4TSHRALOX12SMN1; SMN2 | |
| SCHEMBL1280224 | 0.84 | ALOX12 (0.37) | ALDH1A1CYP3A4TSHRALOX12SMN1; SMN2 | |
| SCHEMBL21261912 | 0.81 | LPAR2 (0.40) | LPAR3LPAR2ALDH1A1CYP3A4TSHR | |
| SCHEMBL11998879 | 0.81 | ALOX12 (0.35) | ALOX12 | |
| SCHEMBL9927889 | 0.80 | FAAH (0.46) | FAAHLMNAMAPTUSP2RECQL | |
| SCHEMBL2037671 | 0.80 | NAAA (0.42) | ALDH1A1CYP3A4TSHRLMNASMN1; SMN2 | |
| SCHEMBL4696869 | 0.80 | ALDH1A1 (0.41) | ALDH1A1TSHRLMNAALOX12SMN1; SMN2 | |
| SCHEMBL18755724 | 0.79 | ALOX12 (0.33) | ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754105-B2 | Macrocyclic inhibitors of hepatitis C virus | MEDIVIR AB (SE) | 2014-06-17 | — | — | US | disclosed |
| US-8754105-B2 | Macrocyclic inhibitors of hepatitis C virus | MEDIVIR AB (SE) | 2014-06-17 | — | — | US | disclosed |
| US-8754105-B2 | Macrocyclic inhibitors of hepatitis C virus | MEDIVIR AB (SE) | 2014-06-17 | — | — | US | disclosed |
| EP-1912996-B1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | JANSSEN R & D IRELAND (IE) | 2012-06-20 | — | — | EP | disclosed |
| US-20110237621-A1 | Macrocyclic Inhibitors of Hepatitis C Virus | JANSSEN SCIENCES IRELAND UC (IE) | 2011-09-29 | — | — | US | disclosed |
| US-20110237621-A1 | Macrocyclic Inhibitors of Hepatitis C Virus | JANSSEN SCIENCES IRELAND UC (IE) | 2011-09-29 | — | — | US | disclosed |
| US-20110237621-A1 | Macrocyclic Inhibitors of Hepatitis C Virus | JANSSEN SCIENCES IRELAND UC (IE) | 2011-09-29 | — | — | US | disclosed |
| US-20100120855-A1 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARMACEUTICALS LTD. | 2010-05-13 | — | — | US | disclosed |
| US-20100120855-A1 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARMACEUTICALS LTD. | 2010-05-13 | — | — | US | disclosed |
| US-20100120855-A1 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARMACEUTICALS LTD. | 2010-05-13 | — | — | US | disclosed |
| WO-2007014920-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120855-A1 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | NR4A1, NR4A3, NR4A2 | LPAR3 2551/4885LPAR2 2519/4885ALDH1A1 2026/4885 |
| US-20110237621-A1 | Macrocyclic Inhibitors of Hepatitis C Virus | NR4A1, NR4A3, NR4A2 | LPAR3 2604/4885LPAR2 2685/4885ALDH1A1 1595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.